<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02840240</url>
  </required_header>
  <id_info>
    <org_study_id>15-479</org_study_id>
    <nct_id>NCT02840240</nct_id>
  </id_info>
  <brief_title>Effect of Gabapentin Enacarbil on Opioid Consumption and Pain Scores</brief_title>
  <official_title>A Randomized Controlled Trial to Determine the Effect of Gabapentin Enacarbil on Opioid Consumption and Pain Scores in Patients Having Hip and Knee Arthroplasties With Spinal Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Opioids are effective analgesics, but cause side effects including sedation, respiratory&#xD;
      depression, low blood pressure, nausea, and constipation. Gabapentin enacarbil, which is a&#xD;
      FDA approved drug for post herpetic neuralgia (nerve pain related to shingles) and restless&#xD;
      leg syndrome, may decrease your need for narcotics and thus decrease the risk of side&#xD;
      effects. The investigator hopes this study will determine if gabapentin enacarbil decreases&#xD;
      opioid consumption and pain after surgery.&#xD;
&#xD;
      Patients having elective hip and knee surgery will be asked to participate in the study.&#xD;
      Patients will be randomized to Gabapentin enacarbil 600mg twice per day for 5 days or Placebo&#xD;
      twice per day for 5 days.&#xD;
&#xD;
      One day prior to surgery the patient will take Gabapentin enacarbil 600mg or placebo 600mg&#xD;
      twice a day with meals. On the day of surgery, the patient will take Gabapentin enacarbil&#xD;
      600mg or placebo 600mg two hours before the surgical procedure. Six hours after the&#xD;
      completion of surgery, the patient will receive Gabapentin enacarbil 600mg or placebo 600mg.&#xD;
      If the patient is sent home, the patient will be given 6 Gabapentin enacarbil 600mg or&#xD;
      placebo 600mg pills to take home along with instructions. However, if the patient remains&#xD;
      hospitalized, on the first day after the surgery, the patient will have pain assessed in the&#xD;
      morning using a numerical rating score. The patient's quality of recovery will be evaluated&#xD;
      using a questionnaire and the patient will receive Gabapentin enacarbil 600mg or placebo&#xD;
      600mg twice a day with meals. The second and third day the patient is in the hospital, the&#xD;
      patient will have pain assessed in the morning using a numerical rating score and the patient&#xD;
      will receive Gabapentin enacarbil 600mg or placebo 600mg twice a day with meals. Then, three&#xD;
      months after surgery, the patient will receive a phone call to follow-up with possible pain&#xD;
      or discomfort the patient may be feeling.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Actual">April 23, 2021</completion_date>
  <primary_completion_date type="Actual">November 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time weighted average pain score in numerical rating scores</measure>
    <time_frame>72 hours after surgery or till discharge, whatever comes first</time_frame>
    <description>Multiple pain measurements (numeric rating scale ranges from 0 to 10, where 0 - no pain and 10 - worse imaginable pain) over 72 hours after the surgery will be summarized by computing time weighted average pain score for each patient</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative postoperative opioid consumption</measure>
    <time_frame>72 hours after surgery or till discharge, whatever comes first</time_frame>
    <description>The total dose of opioid administered in the PACU and floor including the background analgesia (PCA) and boluses. All opioids will be converted into mg intravenous (IV) morphine equivalent to standardize opioid consumption .</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Gabapentin enacarbil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients going through elective hip or knee replacement surgery with spinal anesthesia will receive Gabapentin enacarbil for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients going through elective hip or knee replacement surgery with spinal anesthesia will receive placebo for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin enacarbil</intervention_name>
    <description>600 mg BID 1 day pre-op and 2 hours before surgery, 6 hours after surgery, 600 mg BID 3 days post-operative</description>
    <arm_group_label>Gabapentin enacarbil</arm_group_label>
    <other_name>Xenoport</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>600 mg BID taken 1 day pre-op and 2 hours before surgery, 6 hours after surgery, 600 mg 3 days post-operative</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men or women 18-85 years of age.&#xD;
&#xD;
          2. Scheduled for elective knee or hip arthroplasty with spinal anesthesia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Creatinine &gt;1.50 mg/dl.&#xD;
&#xD;
          2. History of clinically important current depression or currently on any prescribed&#xD;
             anti-depressant medication.&#xD;
&#xD;
          3. Previously enrolled in any Xenoport trial.&#xD;
&#xD;
          4. Use of gabapentin or gabapentinoids (Lyrica, Horizant, Neurontin or Gralise) within&#xD;
             one month.&#xD;
&#xD;
          5. Allergy to gabapentin or gabapentinoids (Lyrica, Horizant, Neurontin or Gralise).&#xD;
&#xD;
          6. Women who are pregnant or breastfeeding.&#xD;
&#xD;
          7. History of seizure disorder within the last one-year or taking medications for&#xD;
             seizures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Sessler, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 23, 2016</study_first_submitted>
  <study_first_submitted_qc>July 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2016</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

